15 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has declined 0.5% per year over the past 5 years.
Operating margin has expanded, at 6.4% in the latest year.
Financial health
Total debt ($939M) exceeds cash ($387M); net debt is $551M.
Total debt has grown slower than revenue (-28.4% vs -0.5% per year).
Operating income covered interest expense 2.8× in the latest year.
Total debt is 2.5× EBITDA.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$3.8B
$95M
25.3%
6.4%
8.6%
2.5%
—
$939M
$387M
2024
$3.8B
-$17M
24.5%
4.9%
-1.8%
-0.5%
—
$927M
$311M
2022
$3.5B
-$581M
21.9%
-6.1%
42.1%
-19.0%
—
$2.6B
$319M
2021
$3.9B
-$79M
26.7%
3.5%
9.3%
-2.2%
—
—
$389M
2020
$3.9B
-$269M
26.5%
0.6%
32.5%
-7.4%
—
—
$325M
2019
$4.4B
-$341M
24.2%
-0.6%
64.4%
-9.0%
—
—
$281M
2018
$4.6B
-$531M
19.6%
-7.1%
355.0%
-12.4%
—
—
$458M
2017
$4.6B
-$242M
21.7%
-2.0%
-54.2%
-4.6%
—
—
$543M
2016
$3.3B
-$42M
21.5%
-5.1%
-7.1%
-0.8%
—
—
$653M
2015
—
$74M
—
—
17.9%
3.3%
—
—
$314M
2014
—
$114M
—
—
21.5%
4.9%
—
—
—
2013
—
-$182M
—
—
-30.4%
-8.3%
—
—
—
2012
—
$74M
—
—
9.3%
2.8%
—
—
—
2011
—
$144M
—
—
17.7%
5.7%
—
—
—
2010
—
-$20M
—
—
-2.1%
-0.8%
$222M
—
—
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Sep '26
$994M
$7M
24.9%
3.9%
0.7%
0.2%
—
$949M
$185M
Jun '26
$931M
$16M
25.7%
6.2%
1.6%
0.4%
—
$943M
$282M
Mar '26
$892M
$5M
23.9%
3.7%
0.5%
0.1%
—
$939M
$374M
Dec '25
$1.1B
$50M
25.3%
7.5%
4.5%
1.3%
—
$939M
$387M
Sep '25
$945M
$41M
25.9%
7.8%
3.7%
1.1%
—
$934M
$263M
Jun '25
$915M
$12M
25.6%
6.1%
1.1%
0.3%
—
$931M
$295M
Mar '25
$841M
-$8M
24.1%
3.5%
-0.8%
-0.2%
—
$929M
$320M
Dec '24
$989M
$6M
23.4%
4.2%
0.6%
0.2%
—
$927M
$311M
Sep '24
$927M
-$22M
25.5%
5.0%
-2.1%
-0.6%
—
$1.1B
$334M
Jun '24
$940M
$15M
25.9%
7.5%
1.5%
0.4%
—
$1.1B
$360M
Mar '24
$895M
-$15M
23.3%
2.7%
-1.4%
-0.4%
—
$1.1B
$388M
Jun '23
$922M
-$677M
24.4%
-0.4%
31.7%
-19.9%
—
$2.2B
$542M
Mar '23
$858M
-$111M
24.4%
-0.2%
7.5%
-3.6%
—
$2574
$246M
Dec '22
$969M
-$149M
22.4%
-4.4%
10.8%
-4.9%
—
$2.6B
$319M
Sep '22
$810M
-$50M
23.9%
0.7%
3.7%
-1.7%
—
—
$128M
Jun '22
$852M
-$199M
18.9%
-10.7%
15.8%
-6.3%
—
—
$250M
Mar '22
$830M
-$183M
22.3%
-10.1%
18.0%
-5.5%
—
—
$225M
Dec '21
$1.1B
-$38M
24.4%
4.7%
4.5%
-1.1%
—
—
$389M
Sep '21
$958M
-$2M
27.1%
4.0%
0.2%
-0.1%
—
—
$216M
Jun '21
$944M
-$30M
26.7%
1.4%
3.6%
-0.9%
—
—
$224M
Valuation over time
How the market has priced DBD against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 24.1× (Dec '25) to 19.9× (Nov '26).
The price-to-sales ratio has risen from 0.0× (Mar '23) to 0.5× (Nov '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Frequently asked questions
Is DBD growing its revenue and profit?
Over the past 5 years, Diebold Nixdorf, Inc's revenue has declined 0.5% per year. These are computed facts, not advice.
How much debt does DBD have?
As of FY2025, Diebold Nixdorf, Inc reported $939M of total debt against $387M of cash; operating income covered interest expense 2.8×.
What is DBD's profit margin?
In FY2025, gross margin was 25.3%, operating margin 6.4%, and net margin 2.5%.
What is DBD's P/E ratio?
Diebold Nixdorf, Inc's P/E (TTM) is 24.50 as of the 2026-11-03 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the DBD stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 19.9× as of Nov '26) can differ. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.